Koyfin Home > Directory > Health Care > Aerie Pharmaceuticals > Long-Term Debt / Capital

Aerie Pharmaceuticals Long-Term Debt / Capital Chart (AERI)

Aerie Pharmaceuticals annual/quarterly Long-Term Debt / Capital from 2014 to 2020.
  • Aerie Pharmaceuticals Long-Term Debt / Capital for the quarter ending June 06, 2020 was $69m a 30.71% increase of 21m year over year
  • Aerie Pharmaceuticals Long-Term Debt / Capital for the last 12 months ending June 06, 2020 was $69m a 30.71% increase of 21m year over year
  • Aerie Pharmaceuticals Annual Long-Term Debt / Capital for 2019 was $54m a 11.26% increase of 6m from 2018
  • Aerie Pharmaceuticals Annual Long-Term Debt / Capital for 2017 was $48m a -13.07% decrease of -6m from 2016
  • Aerie Pharmaceuticals Annual Long-Term Debt / Capital for 2016 was $54m a -60.78% decrease of -33m from 2015
Other Ratios Metrics:
  • Aerie Pharmaceuticals Total Debt / Capital for the quarter ending June 06, 2018 was $39m a -12.45% decrease of -5m year over year
  • Aerie Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $6m a 11.47% increase of 1m year over year
  • Aerie Pharmaceuticals Total Debt / Equity for the quarter ending June 06, 2018 was $64m a -22.13% decrease of -14m year over year
View Chart On Koyfin

Quarterly AERI Long-Term Debt / Capital Data

06/2020$69m
03/2020$61m
12/2019$54m
09/2019$48m
06/2019$8m
03/2019$6m
06/2018$39m
03/2018$34m
12/2017$48m
09/2017$44m

Annual AERI Long-Term Debt / Capital Data

2019$54m
2017$48m
2016$54m
2015$87m
2014$81m